Genscript Biotech (GNNSF) Stock Price, News & Analysis

Company Overview

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries. In parallel, GenScript delivers biologics process development and manufacturing under current Good Manufacturing Practice (cGMP) standards, offering fermentation, cell culture and downstream purification capabilities for both viral and non-viral products. Its antibody discovery arm leverages phage display and hybridoma technologies, supported by on-site analytical characterization and bioassay development.

Headquartered in Piscataway, New Jersey, and Nanjing, China, GenScript operates a network of research and production facilities across North America, Europe and Asia. The company holds numerous quality certifications, including ISO 9001 and cGMP compliance, reflecting its commitment to regulatory standards. Over nearly two decades, GenScript has expanded through strategic investments in automation and bioinformatics, positioning itself as a one-stop partner for organizations pursuing novel therapeutics and diagnostic reagents.

Key Stats

• Today's Range: C$1.73 to C$1.73
• 50-Day Range: C$1.30 to C$1.75
• 52-Week Range: C$1.30 to C$2.42
• Volume: 1,000 shs
• Average Volume: 7,467 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNNSF Stock Analysis - Frequently Asked Questions

How have GNNSF shares performed this year?

Genscript Biotech's stock was trading at C$1.67 at the beginning of 2026. Since then, GNNSF shares have increased by 3.6% and is now trading at C$1.73.

How do I buy shares of Genscript Biotech?

Shares of GNNSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNNSF
• CIK: N/A
• Web: www.genscript.com
• Phone: 862558897288
• Fax: N/A
• Employees: 6,937
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A